Nektar Therapeutics to Participate in Two Investor Conferences in March

SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami. TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m.

PRNewsWire • an hour ago

Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy

Nektar Therapeutics (NKTR) is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. REZPEG's unique mechanism expands regulatory T cells, aiming for durable immune balance rather than rapid symptom suppression, like current IL4/13 inhibitors. While REZPEG's induction data was only moderate versus competitors, its maintenance data confirms the intended, differentiated mechanism of action.

Seeking Alpha • Feb 18, 2026

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L. Hauser, M.D.

PRNewsWire • Feb 17, 2026

Can NKTR Stock Sustain Its 1,000% Rally?

Nektar stock has increased more than 100% within a week and has skyrocketed 1,000% from its 52-week low of $6.50, trading at around $71 as of February 13, 2026. The surge intensified following the company's release of 36-week maintenance data from the REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis.

Forbes • Feb 13, 2026

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar sold 7,637,931 shares of common stock in the offering, which includes 1,034,482 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and 293,103 pre-funded warrants.

PRNewsWire • Feb 13, 2026

Why Is Nektar Therapeutics Stock Gaining Wednesday?

Nektar Therapeutics  (NASDAQ: NKTR) stock surged in premarket trading Wednesday after new long-term data showed its experimental eczema therapy delivered sustained and even deepening disease control through one year, strengthening its competitive positioning in the multibillion-dollar atopic dermatitis market.

Benzinga • Feb 11, 2026

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar is selling 6,603,449 shares of common stock and 293,103 pre-funded warrants in the offering.

PRNewsWire • Feb 12, 2026

Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock?

Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • Feb 11, 2026

Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript

Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript

Seeking Alpha • Feb 10, 2026

Nektar Therapeutics Announces Proposed Public Offering

SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of $300,000,000 of its shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Nektar.

PRNewsWire • Feb 10, 2026